生物与传统疗法:比较牛皮相关并发症风险
Journal of drugs in dermatology : JDD
|June 5, 2023
概括
接受生物治疗的牛皮患者比接受常规治疗的患者表现出较少的并发症. 这项研究表明,生物药物可以在牛皮护理中更好地管理相关健康状况.
科学领域:
- 皮肤病学 皮肤病学
- 临床免疫学临床免疫学
- 流行病学 流行病学
背景情况:
- 牛皮是一种慢性炎症状况,与许多并发症有关.
- 了解不同治疗方式对这些并发症的影响对于全面的患者护理至关重要.
研究的目的:
- 为了比较用生物疗法治疗的牛皮病患者与传统疗法治疗的并发症的患病率.
- 评估生物治疗与降低并发症率之间的潜在关联.
主要方法:
- 对患有牛皮的患者进行回顾性队列分析.
- 在接受生物治疗和接受常规治疗的患者之间比较并发症数据.
主要成果:
- 与传统治疗治疗的患者相比,使用生物疗法治疗的患者表现出较低的并发病率.
- 这些数据表明,生物制剂在管理与牛皮相关的健康状况方面具有潜在的益处.
结论:
- 生物治疗可能与牛皮患者的并发症负担减少有关.
- 需要进一步的研究来证实这些发现并阐明涉及的机制.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
150
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
150
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
204
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
204
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
Inflammatory Bowel Disease IV: Pharmacological Management
159
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
159
Comparing the Survival Analysis of Two or More Groups
228
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
228


